| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.22 | 0.0003 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.37 | 0.0009 |